^
BIOMARKER:

RET M918T

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Entrez ID:
RET M918T
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
RET M918T
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: C3 – Early Trials
RET M918T
Thyroid Gland Medullary Carcinoma
sorafenib
Sensitive: C3 – Early Trials
RET M918T
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: C3 – Early Trials
RET M918T
Thyroid Gland Medullary Carcinoma
everolimus + vandetanib
Sensitive: C4 – Case Studies
RET M918T
Thyroid Gland Medullary Carcinoma
everolimus
Sensitive: C4 – Case Studies
RET M918T
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: C4 – Case Studies
RET M918T
Thyroid Gland Medullary Carcinoma
sunitinib
Sensitive: C4 – Case Studies
RET M918T
Thyroid Gland Carcinoma
XMD15-44
Sensitive: D – Preclinical
RET M918T
Thyroid Gland Medullary Carcinoma
AMG 706
Resistant: D – Preclinical
RET M918T
Thyroid Gland Carcinoma
HG-6-63-01
Sensitive: D – Preclinical
RET M918T
Thyroid Gland Papillary Carcinoma
AZD1480
Sensitive: D – Preclinical
RET M918T
Thyroid Gland Carcinoma
ALW-II-41-27
Sensitive: D – Preclinical